Vol. 2 No. 8 (2022)
Reimbursement Recommendations

Mogamulizumab (Poteligeo)

Published August 30, 2022

Key Messages

  • CADTH recommends that Poteligeo should be reimbursed by public drug plans for the treatment of relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) if certain conditions are met.
  • Poteligeo should only be covered to treat adult patients with MF or SS who have already tried at least 1treatment that did not work or in whom the disease has come back. Patients receiving Poteligeo should be in relatively good health (i.e., have a good performance status, as determined by a specialist).
  • Poteligeo should only be reimbursed if prescribed by a specialist and if the price of Poteligeo is reduced.